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The impact of organisational external peer
review on colorectal cancer treatment
and survival in the Netherlands
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1Department of Research, Comprehensive Cancer Centre the Netherlands, Postbus 19079, 3501 DB Utrecht, The Netherlands;
2Department of Health Technology and Services Research, School for Management and Governance, University of Twente,
Drienerlolaan 5, 7522 NB Enschede, The Netherlands; 3Department of Epidemiology, University Medical Centre Groningen,
University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands and 4Division of Psychosocial Research and
Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Background: Organisational external peer review was introduced in 1994 in the Netherlands to improve multidisciplinary
cancer care. We examined the clinical impact of this programme on colorectal cancer care.
Methods: Patients with primary colorectal cancer were included from 23 participating hospitals and 7 controls. Hospitals from the
intervention group were dichotomised by their implementation proportion (IP) of the recommendations from each peer review
(high IP vs low IP). Outcome measures were the introduction of new multidisciplinary therapies and survival.
Results: In total, 45 705 patients were included (1990–2010). Patients from intervention hospitals more frequently received adjuvant
chemotherapy for stage III colon cancer. T2–3/M0 rectal cancer patients from hospitals with a high IP had a higher chance of
receiving preoperative radiotherapy (OR 1.31, 95% CI 1.11–1.55) compared with the controls and low IP group (OR 0.75, 95% CI
0.63–0.88). There were no differences in the use of preoperative chemoradiation for T4/M0 rectal cancer. Survival was slightly
higher in colon cancer patients from intervention hospitals but unrelated to the phase of the programme in which the hospital was
at the time of diagnosis.
Conclusions: Some positive effects of external peer review on cancer care were found, but the results need to be interpreted
cautiously due to the ambiguity of the outcomes and possible confounding factors.
Delivering high quality care is key to modern health-care
system. External quality assessment programmes are more and
more considered as a cornerstone in the assessment and
improvement of quality. Internationally, accreditation is the most
commonly used method. In the Netherlands, external peer review
(visitatie in Dutch, meaning ‘to visit’) is the dominant external
quality assessment method and this approach is slowly gaining
popularity in Europe (Heaton, 2000; van Weert, 2000). Organisa-
tional external peer review for cancer care was introduced in the
Netherlands in 1994. In England, National Cancer Peer Review
(NCPR) was introduced as a part of the National Cancer
Programme in 2004, after a first round of peer review was
conducted at a regional level in 2001 (National Cancer Peer
Review Programme, 2012). The English programme focusses on
performance for specific tumour groups, whereas the Dutch
programme targets the multidisciplinary cancer care organisation
in hospitals as a whole.
When the external peer review programme was introduced in
the Netherlands in 1994, treatment of cancer patients was
predominantly monodisciplinary. Since then, multidisciplinary
cancer care has become the standard. The programme was
introduced by the Comprehensive Cancer Centre North Nether-
lands. The nine Comprehensive Cancer Centres, covering the
whole Netherlands, are regional network organisations of health-
care professionals and institutes for cancer and palliative care
aiming at improving cancer care through research, guideline
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development, knowledge exchange and organisational improve-
ment without having a treatment function themselves. The peer
review programme was first introduced in the Northern Nether-
lands and gradually spread over the country. Surveyors are all
specially trained medical and nursing specialists, which results in a
natural understanding of the daily challenges faced in the
treatment of cancer patients; in this way the system is supposed
to generate recognition and involvement of professionals. Partici-
pation is voluntary and hospitals are advised to participate every
4–5 years. A majority of Dutch hospitals has gone through the
procedure at least once and in some regions already thrice. Using
self-assessment, on-site observation and interviews, the state of
cancer care in a hospital is evaluated and recommendations for
improvement are given. Major topics of recommendations were
the organisation of weekly multidisciplinary patient care meetings,
shared decision making between specialists, oncological specialisa-
tion of medical specialists, dedication of oncology committees to
policy making, introduction of integrated care pathways, referral
policies for low volume tumours and highly complicated interven-
tions and working according to evidence-based guidelines.
Few studies have been published on the clinical impact of
external peer review. Roberts et al (2010, 2012) report on the
1- and 3-year evaluation of peer review for chronic obstructive
pulmonary disease in the United Kingdom. Findings after 3 years
indicated an association with improved quality of care, service
delivery and changes that promote quality improvement (Roberts
et al, 2012). The 1-year evaluation revealed no differences showing
that changes need a longer period to occur (Roberts et al, 2010).
More studies have been done on the effects of accreditation but the
evidence remains uncertain (Greenfield and Braithwaite, 2008;
Hinchcliff et al, 2012). Due to high financial and labor investments,
calls have been made for more research concerning the clinical
impact of these programmes (Shaw, 2001; Greenfield and
Braithwaite, 2009).
The purpose of our study is to investigate whether (1) the
participation in the external peer review programme focussing on
multidisciplinary cancer care and (2) the extent of the implemen-
tation of the peer review recommendations impacted multi-
disciplinary treatment patterns (such as combined treatment
modalities) and survival of colorectal cancer patients. Colorectal
cancer was among the first type of cancer requiring multi-
disciplinary treatment. Due to new treatments, the quality of care
has improved significantly in the last 20–30 years (Elferink et al,
2010a; van Steenbergen et al, 2010a). Studies have proven that
regional and inter-hospital treatment variation exists that cannot
be explained by medical factors only. It is suggested that hospital
characteristics have a role in this variation (Elferink et al, 2010b,
2010c). Three major therapy changes requiring multidisciplinary
cooperation have been introduced in the period under study:
(1) the introduction of adjuvant chemotherapy in stage III colon
cancer, (2) the introduction of preoperative radiotherapy in T2–T3
rectal cancer and (3) the introduction of preoperative chemoradia-
tion in T4/M0 rectal cancer and tumours with an expected positive
circumferential margin (CRM) (National Working Group on
Gastrointestinal Cancer, 2012). We hypothesised that the willing-
ness of a hospital to have external peer review and to follow the
recommendations from it is correlated with the hospital giving
higher quality of colorectal cancer treatment measured by the
introduction of new multidisciplinary therapies and better survival
of the colorectal cancer patients.
MATERIAL AND METHODS
Design and patients. We selected all patients diagnosed with
primary invasive epithelial colorectal cancer (ICD-O3 codes: colon
C18.0–18.9, rectum C20.9) between 1 January 1990 and 31
December 2010 from the population-based Netherlands Cancer
Registry. Patients diagnosed at autopsy, during an emergency
operation or with previous malignancies were excluded. Patients
from hospitals from the two regions where the programme was
introduced first (Northern Netherlands and Rotterdam/South-west
regions) form the intervention group. All hospitals in these
regions voluntarily participated in the programme. The control
group consists of patients from seven hospitals with
otherwise comparable characteristics that did not participate
before 2009, because the programme as such was not yet available
in all regions.
Within the Netherlands Cancer Registry clinical administrative
data of every newly diagnosed cancer patient in the Netherlands
are collected. Topography and morphology are coded according to
the International Classification of Diseases for Oncology and
staging according to the TNM classification. Follow-up of vital
status is achieved by linking the registry to municipal records.
Quality of the data is high (Schouten et al, 1993a) and data
completeness is estimated to be at least 95% (Schouten et al,
1993b).
The treatment and survival analyses are based on the hospital
where the patient was diagnosed. Some patients may have been
referred for treatment but this is considered as a good standard of
care of the referring hospital. Furthermore, referral policies for low
volume tumours were an important topic of the external peer
review programme. We used the implementation proportion (IP)
of all the recommendations given in the final reports of each peer
review as a measure for the willingness of a hospital to implement
the recommendations and the quality of colorectal cancer care.
Data on the IP were obtained by studying the peer review reports,
follow-up correspondence, hospital documents and interviews with
stakeholders. Implementation was ranked per recommendation on
a scale from 0 to 4 in which 4 represents total implementation and
0 a not implemented recommendation (Appendix 1). Scores per
hospital were expressed as a percentage of the total score that could
be achieved. When implementation of a recommendation could
not be assessed (no data), the recommendation was subtracted
from the total possible score. We used the average IP of all peer
reviews per hospital because the time period in which changes can
occur is unknown and quality improvement is a continuous
process. Data from three cycles of peer review (1994–2009) were
used from the Northern Netherlands and data from two cycles
(1996–2006) from the Rotterdam region. A third cycle was
completed in the Rotterdam region between 2009 and 2011 but
the follow-up time was too short to monitor the IP. We did not
make assumptions on what a high or a low IP is and therefore
dichotomised the hospitals in the intervention group into
two categories: (1) hospitals with the highest IP and (2) with the
lowest IP.
Hospitals were asked for permission to use their data from
the Netherlands Cancer Registry and programme reports. We
excluded university hospitals and hospitals that merged during our
study period since it was impossible to determine the IP.
Multidisciplinary treatment patterns. We studied the impact of
the programme on the introduction of three major changes in
multidisciplinary treatment: (1) adjuvant chemotherapy in stage III
colon cancer, (2) preoperative radiotherapy in T2-T3/M0 rectal
cancer and (3) preoperative chemoradiation in T4/M0
rectal cancer. Preoperative chemoradiation is also recommended
in rectal cancer patients with tumours with an expected positive
CRM (other than T4 tumours) but the Netherlands Cancer
Registry does not provide data on the expected margin. We
therefore focussed on the T4/M0 patients for the implementation
of the preoperative chemoradiation. All patients with T2–3/M0
tumours, irrespective of their CRM, are therefore included in the
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analyses for preoperative radiotherapy as this is the minimal
treatment they should have received.
Survival. The association between the programme and the
survival was evaluated for the complete cohort subdivided into
colon and rectal cancer patients. To examine the impact of the
different programme phases on survival, we compared the 5-year
survival of patients with the phase in which the hospital was at the
time of diagnosis.
Statistical analyses. Clinical stage was used in our analyses for
preoperative radiotherapy for T2–3/M0 rectal cancer patients and
preoperative chemoradiation for T4/M0 rectal cancer patients.
In case clinical stage was unknown it was substituted by
pathological stage. Pathological stage was used for analysing the
use of adjuvant chemotherapy in stage III colon cancer and
survival, clinical stage was used when pathological stage was
unknown. We excluded patients agedX75 years for the analyses of
the introduction of chemotherapy in stage III colon cancer and
chemoradiation in T4/M0 rectal cancer to prevent a bias as elderly
patients are known to receive systemic therapy less frequently
(Elferink et al, 2010b, c).
Multivariate logistic analysis was used to analyse the variation in
treatment and the influence of participating in the programme and
the IP, corrected for gender, age at diagnosis, year of diagnosis,
average hospital volume of diagnoses and the presence of an
in-hospital radiotherapy department. Because all analyses concern
adjuvant therapy, only operated patients are included in the
treatment analyses.
Using Cox’s proportional hazards model, we examined
differences in hazard of dying adjusted for gender, age at diagnosis,
year of diagnosis and average annual hospital volume of diagnoses.
Survival time was defined as the period from incidence to date of
death (all causes) or censuring (31 December 2011 or emigration
date). For all analyses, STATA version 12.0 (StataCorp, College
Station, TX, USA) was used.
RESULTS
Population. We requested permission of 26 hospitals from the
Northern Netherlands and Rotterdam region to use the data from
their peer reviews and the Netherlands Cancer Registry, 23
hospitals gave their permission. Seven out of twelve hospitals
without experience with the programme agreed to be included in
the control group. In total, 45 705 patients were diagnosed with
colorectal cancer in these 30 hospitals (about 1 out of 3 of all
hospitals in the Netherlands) between 1990 and 2010, 31 890
patients with colon cancer and 13 815 patients with rectal cancer.
A schematic overview of the study population at each phase of our
study is presented in Appendix 2.
Implementation of programme recommendations. In the three
cycles of peer review in the Northern Netherlands and two cycles
in the Rotterdam region 727 recommendations were given to the
hospitals. This is an average of 12 recommendations per peer
review per hospital. The intervention group was dichotomised in
12 hospitals with a high IP (average 62.6%) and 11 hospitals with a
low IP (average 44.8%). Table 1 shows the patient characteristics of
the population of colon and rectal cancer patients for the
intervention and control groups.
Multidisciplinary treatment patterns. Out of the colon cancer
patients, 4969 surgically treated patients under 75 years of age
patients had stage III. Patients with stage III colon cancer who were
diagnosed in hospitals in the intervention group received adjuvant
chemotherapy more frequently compared with the control group
(Table 2). This was seen in both the high IP and the low IP
intervention hospitals (OR 1.48, 95% CI 1.25–1.75 and OR 1.19,
Table 1. Characteristics of the cohorts of colon (N¼ 31 890) and rectal




group – High IP
(12 hospitals)
Intervention






Male 5555 (48.4) 5211 (48.8) 4835 (49.7)
Female 5924 (51.6) 5463 (51.2) 4902 (50.3)
Mean age at diagnosis
o60 2071 (18.0) 1939 (18.2) 1907 (19.6)
60–74 4694 (40.9) 4520 (42.3) 4309 (44.3)
474 4714 (41.1) 4215 (39.5) 3521 (36.2)
Period of diagnosis
1990–1995 2710 (23.6) 2381 (22.3) 2100 (21.6)
1996–2001 3080 (26.8) 2867 (26.9) 2559 (26.3)
2002–2007 3535 (30.8) 3472 (32.5) 3051 (31.3)
2008–2010 2154 (18.8) 1954 (18.3) 2027 (20.8)
Stage
1 1761 (15.3) 1683 (15.8) 1317 (13.5)
2 4026 (35.1) 3823 (35.8) 3626 (37.2)
3 2945 (25.7) 2694 (25.2) 2421 (24.9)
4 2392 (20.8) 2174 (20.4) 2055 (21.1)
Carcinoid 36 (0.3) 30 (0.3) 29 (0.3)
Unknown 319 (2.8) 270 (2.5) 289 (3.0)
Average annual volume of hospital of diagnosis
o50 6070 (52.9) 6856 (64.2) 2437 (25.0)
50 or more 5409 (47.1) 3818 (35.8) 7300 (75.0)
Rectal cancer
Sex
Male 2804 (57.2) 2696 (58.8) 2597 (60.0)
Female 2100 (42.8) 1888 (41.2) 1730 (40.0)
Mean age at diagnosis
o60 1192 (24.3) 1087 (23.7) 1153 (26.7)
60–74 2099 (42.8) 2050 (44.7) 1975 (45.6)
474 1613 (32.9) 1447 (31.6) 1199 (27.7)
Period of diagnosis
1990–1995 1045 (21.3) 977 (21.3) 896 (20.7)
1996–2001 1274 (26.0) 1183 (25.8) 1077 (24.9)
2002–2007 1628 (33.2) 1511 (33.0) 1372 (31.7)
2008–2010 957 (19.5) 913 (19.9) 982 (22.7)
Stage
1 1352 (27.6) 1324 (28.9) 1135 (26.2)
2 1139 (23.2) 1089 (23.8) 1058 (24.5)
3 1262 (25.7) 1127 (24.6) 998 (23.0)
4 808 (16.5) 762 (16.6) 756 (17.5)
Carcinoid 13 (0.3) 18 (0.4) 18 (0.4)
X 330 (6.7) 264 (5.8) 362 (8.4)
Average annual volume of hospital of diagnosis
o25 3039 (62.0) 3829 (83.5) 1572 (36.3)
425 1865 (38.0) 755 (16.5) 2755 (63.7)
Abbreviation: IP¼ implementation proportion.
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95% CI 1.00–1.41, respectively). An early adopter effect is seen in
Figure 1 between 1990 and 2000, but the effect is also seen in the
later years. Concerning the rectal cancer patients, 7804 patients
were included in our treatment analyses with stage T2–T3/M0
cancer and 689 with T4/M0 rectal cancer. The analyses of the use
of preoperative radiotherapy for T2–T3/M0 rectal cancer initially
showed no difference between the control group and the
intervention group (Table 2). Here the IP mattered as can be seen
in Figure 2; patients who were diagnosed in the intervention
hospitals with a high IP received preoperative radiotherapy more
often (OR 1.31, 95% CI 1.11–1.55) while patients of intervention
hospitals with a low IP had a lower chance (OR 0.75, 95% CI 0.63–
0.88) compared with the control group. No differences were seen in
the use of preoperative chemoradiation for T4/M0 rectal cancer
patients (Table 2). Figure 3 shows that after the year 2000 the
proportion of patients receiving preoperative chemoradiation rose
but no statistically significant differences were seen between the
intervention and control groups (Table 2).
Survival. The hazard of dying for patients with colon cancer was
slightly lower in the intervention group compared with the control
group (HR 0.97, 95% CI 0.94–0.99; Table 3). No statistical
significant differences were found in the hazard of dying of rectal
cancer between the intervention and the control groups (Table 3).
Furthermore, there was no correlation seen between the average
5-year survival and the programme phases for both colon and
rectal cancer (Figures 4 and 5).
DISCUSSION
To our knowledge, we present a unique long-term evaluation of the
relationship between external peer review and treatment and
survival of cancer patients based on the population-based data.
There are some indications that the peer review increased process-
related quality of care. Participation in the peer-review programme
and the proportion of implementation of recommendations were
associated with a higher proportion of stage III colon cancer
patients who received adjuvant chemotherapy, whereas for rectal
cancer the implementation of recommendations seems more
relevant as patients diagnosed in hospitals with a high IP received
preoperative radiotherapy more often. On the other hand, we did
not find a difference in the percentage of patients receiving
preoperative chemoradiation for T4/M0 rectal cancer related to
participation or IP. Furthermore, a survival difference could only
be shown for colon cancer, but not for rectal cancer and this did
not seem to correlate with the phase of the programme.
Table 2. Odd’s ratio’s (OR) for receiving new multidisciplinary treatment
per hospital category, adjusted for age, gender, year of diagnosis,
average annual hospital volume of diagnoses
Hospital category OR 95% CI
Adjuvant chemotherapy stage III colon carcinoma
Control group 1.00 Reference
Intervention group 1.33* 1.15–1.55
High IP 1.48* 1.25–1.74
Low IP 1.19* 1.00–1.41
Preoperative radiotherapy T2–T3/M0 rectal cancer
Control group 1.00 Reference
Intervention group 0.98 0.96–1.14
High IP 1.31* 1.11–1.55
Low IP 0.75* 0.63–0.88
Preoperative chemoradiation T4/M0 rectal cancer
Control group 1.00 Reference
Intervention group 1.27 0.81–2.01
High IP 1.11 0.89–2.46
Low IP 1.48 0.67–1.83
Abbreviations: CI¼ confidence interval; IP¼ implementation proportion of recommenda-
tions. Adjustment for the presence of in-hospital radiotherapy department has been made










































































Controls Intervention low IP
Intervention high IP
Figure 1. Introduction of adjuvant chemotherapy for stage III colon cancer (standard since 1990) per hospital category based on the
implementation proportion (IP) of recommendations given in the programme. *represents statistical significance per year (Po0.05).
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A complicated association exists between external peer review,
multidisciplinary care patterns and survival outcomes as many
internal and external factors may be influential. Some differences
in stage III colon cancer treatment for instance were already
apparent before the introduction of the programme in 1994
(Figure 1). Does the programme as such have added value or do
quality oriented hospitals also act as early adopters and simply
implement recommendations better? The absence of a baseline
measurement of organisational quality and innovative behaviour
makes it impossible to answer this question. Based on our findings
either relation is possible, but we tend to conclude that quality
focussed hospitals are more likely to work on continuous quality
improvement and to behave as early adopters.
Inter-hospital and regional variation in the treatment of
colorectal cancer patients was shown in previous national studies











































































Controls Intervention low IP
Intervention high IP
Figure 2. Introduction of preoperative radiotherapy in T2–T3/M0 rectal cancer per hospital category based on the implementation








































Controls Intervention low IP
Intervention high IP
Figure 3. Introduction of preoperative chemoradiation in T4/M0 rectal cancer (recommend since 2005) per hospital category based on the
implementation proportion (IP) of recommendations given in the programme. *represents statistical significance per 5-year period.
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variation in guidelines and in their implementation in the
Netherlands. This might partly explain differences in the results
for adjuvant chemotherapy for stage III colon cancer as these are
most prominent before the year 2000. The results in our study may
also have been influenced by clinical trials conducted before official
guideline recommendation. However, despite possible guideline
and trial influences, recent studies still stress the patient- and
hospital-dependent variation in adjuvant therapy, even after
official guideline introduction of new therapies in the Netherlands
and it is unlikely that this is different in other countries (Lemmens
et al, 2005; Berrino et al, 2007; Elferink et al, 2010b, 2010c; van
Steenbergen et al, 2010b). Although it is unlikely that guideline
and trial influences alone can explain the treatment variation, it is
very difficult to correct for these factors in studying the impact of
peer review.
The average 5-year survival of colon and rectal cancer patients
did not appear to be related to the phase of the peer review
programme in which the hospital was at the time of diagnosis.
Hazard ratio comparisons showed a significant difference in the
risk of dying from colon cancer, favouring patients diagnosed in
the intervention group. In rectal cancer, hazard ratios were
comparable but not statistically different between the intervention
and control groups. These differences are small and promising but
need to be considered with caution. We analysed the risk of dying
in the complete cohorts of colon or rectal cancer patients instead of
the subgroups in which we studied the introduction of new
multidisciplinary therapies. Reason for this is that especially in
rectal cancer these new therapies predominantly have an effect on
Table 3. Hazard ratio’s (HR) for colon and rectal cancer patients per
hospital category, adjusted for age, gender, year of diagnosis and
average annual hospital volume of diagnoses
Hospital category HR 95% CI
Colon cancer
Control group 1.00 Reference
Intervention group 0.97* 0.94–1.00
High IP 0.97 0.93–1.00
Low IP 0.96* 0.93–1.00
Rectal cancer
Control group 1.00 Reference
Intervention group 0.96 0.92–1.01
High IP 0.98 0.93–1.03
Low IP 0.96 0.91–1.01














































































































































































































Figure 5. Average 5-year survival of rectal cancer patients per hospital category and phase of the programme at the time of diagnosis.
IP¼ implementation proportion.
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local control. Adjuvant chemotherapy is associated with improved
survival in stage III colon cancer (Moertel et al, 1990). For
rectal cancer, the benefit of preoperative radiotherapy and
chemoradiation is mainly local control, the impact on survival is
smaller and the evidence is more ambiguous (Colorectal Cancer
Collaborative Group, 2001; Kapiteijn et al, 2001; Folkesson et al,
2005; Bosset et al, 2006).
The main weakness of our study (and most studies in this field)
is that the impact of other, and possibly many, confounding factors
could not be assessed. Survival and mortality are generally used as
the ultimate indicators of quality of care in cancer studies, but are
influenced by a complex set of internal and external factors
and it is difficult to single out the programme impact. Hospitals in
the control group are likely to have introduced changes in their
organisation as well, but we are not aware of similar programmes
that have been executed. Five hospitals from the approached
control group and three from the approached intervention group
did not give permission to use data from the NCR which might
influenced our results, though the participating set seemed
sufficiently representative for the Dutch situation.
Our research had several characteristics adding to a better
understanding of the added value of the programme. It was
possible to include patients from hospitals without experience in
participating in the programme, creating a quasi-experimental
situation. Because all hospitals in the intervention region
participated in the programme (even though three did not give
permission to use their data in this study), there was no
programme participation bias. The Netherlands Cancer Registry
provided us with reliable data over a long time period making it
possible to analyse our results on a ‘patient-level’. We did not
single out recommendations and neither did we address a ‘rank’ of
importance to them to assess the programme impact instead of the
impact of single recommendations.
CONCLUSION
Organisation focussed external quality assessment programmes
have difficulties in demonstrating their added value on clinical
care. All hospitals are willing to participate in external peer review
but the proportion of implementation of recommendations of the
programme differs. Our data show that some positive effects on
cancer care can be expected but the results need to be interpreted
cautiously. Future research on different types of cancer should
assess whether our results can be generalised. A qualitative study
can examine the perceived impact and influence on the sense of
ownership among cancer specialists.
Improved organisation may be a value per se, especially in
complex multidisciplinary treatment. However, if external quality
assessment should provide measurable benefits for individual
cancer patients, programmes probably need to focus more on
specific aspects of the delivery of care and clinical outcomes.
This will increase the possibilities to quantitatively evaluate the
impact on the quality of care. Links with clinical audit systems
and national cancer registries may lead to the reduction in
administrative workload of these programmes and improved
acceptance for continued external peer review for cancer care in
the future.
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0 Not implemented at all
1 Hospital only started working on implementing
2 A recommendation consists of two parts and one
is implemented
3 Recommendation is implemented but not yet
in the entire organisation
4 Complete implementation
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APPENDIX 2
Schematic overview of the study population at each phase of the study
Patients with primary invasive colorectal cancer N = 45705




Stadium III colon cancer 
Intervention high IP N= 2945
Intervention low IP N= 2694
Control N= 2421
Stadium III colon cancer <75yr
Intervention high IP N= 1777
Intervention low IP N= 1668
Control N=1586
T2/T3 rectal cancer 
Intervention high IP N=2869
Intervention low IP N=2649
Control N=2625
T4/M0 rectal cancer 
Intervention high IP N= 471
Intervention low IP N= 433
Control N=328
T4/M0 rectal cancer <75yr
Intervention high IP N= 308








Stadium III colon cancer <75yr
Intervention high IP N= 1762




Intervention high IP N=2730
Intervention low IP N=2555
Control N=2519
Received surgery
T4/M0 rectal cancer <75yr
Intervention high IP N= 241
Intervention low IP N= 240
Control N=208
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